Memory T cells targeting oncogenic mutations detected in peripheral blood of epithelial cancer patients.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30683863.
- Also identified by DOI 10.1038/s41467-019-08304-z and PMC identifier 6347629.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
T cells targeting shared oncogenic mutations can induce durable tumor regression in epithelial cancer patients. Such T cells can be detected in tumor infiltrating lymphocytes, but whether such cells can be detected in the peripheral blood of patients with the common metastatic epithelial cancer patients is unknown. Using a highly sensitive in vitro stimulation and cell enrichment of peripheral memory T cells from six metastatic cancer patients, we identified and isolated CD4<sup>+</sup>, and CD8<sup>+</sup> memory T cells targeting the mutated KRAS<sup>G12D</sup> and KRAS<sup>G12V</sup> variants, respectively, in three patients. In an additional two metastatic colon cancer patients, we detected CD8<sup>+</sup> neoantigen-specific cells targeting the mutated SMAD5 and MUC4 proteins. Therefore, memory T cells targeting unique as well as shared somatic mutations can be detected in the peripheral blood of epithelial cancer patients and can potentially be used for the development of effective personalized T cell-based cancer immunotherapy across multiple patients.
Medical subject headings
- CD4-Positive T-Lymphocytes
- CD8-Positive T-Lymphocytes
- Colonic Neoplasms
- Gene Expression Regulation, Neoplastic
- Mucin-4
- Proto-Oncogene Proteins p21(ras)
- Smad5 Protein